Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Neoadjuvant Ifosfamide and Doxorubicin in Localized High-grade Soft Tissue Sarcoma of Extremities and Trunk Wall

NCT04776525 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT04776525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Neoadjuvant Ifosfamide and Doxorubicin in Localized High-grade Soft Tissue Sarcoma of Extremities and Trunk Wall
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2021
Completion date
September 30, 2036
Enrollment
49 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma